GlassScriptPhysician profile
Paul Lieber
NPI 1932107588
$1,254.71
in general payments reported to CMS, 2019-2025
14 companies · $33.39 in 2025
The $33.39 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $136 · 2021: $196 · 2022: $176 · 2023: $227 · 2024: $16.83 · 2025: $33.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $277.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $727.56 | 2019-2023 | Proclaim |
| Vertos Medical, INC. | $152.54 | 2021 | |
| Abbvie INC. | $66.78 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $51.33 | 2019-2020 | |
| Mdd US Operations, LLC | $44.46 | 2019 | |
| Horizon Therapeutics Plc | $38.78 | 2020 | |
| Collegium Pharmaceutical, INC. | $35.16 | 2019 | |
| Relievant Medsystems, INC. | $31.38 | 2023 | Intracept |
| Nevro Corp. | $29.67 | 2022 | |
| Bioventus LLC | $21.58 | 2023 | Stimrouter Implantable Kit |
| Si-Bone, INC. | $17.60 | 2020 | |
| Pfizer INC. | $15.06 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $11.79 | 2019 | |
| Allergan, INC. | $11.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lieber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.